Clinical News-CliniExpert

GSK Announces New Data Presentations from the DREAMM Programme Exploring Investigational Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma

04 June 2020 -- GlaxoSmithKline (GSK) plc today announced new data from its DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical trial programme of belantamab mafodotin in relapsed/r

AstraZeneca Takes Next Steps Towards Broad and Equitable Access to Oxford University’s COVID-19 Vaccine

4 June 2020 -- AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements with the Coalit

ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis

GENEVA, Switzerland and BOSTON, MA (June 4, 2020) -- ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive he

INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine (INO-4800) in South Korea

SEOUL, South Korea and PLYMOUTH MEETING, Pa., June 4, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnersh

Novavax Awarded Department of Defense Contract for COVID-19 Vaccine

GAITHERSBURG, Md., June 04, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announc

Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology

NEW YORK--(BUSINESS WIRE) June 03, 2020 -- Pfizer Inc. (NYSE: PFE) announced today that JAMA Dermatology has published complete results from the second Phase 3 monotherapy pivotal study (JADE MONO-2)

BerGenBio Confirms First Covid-19 Patient Dosed With Bemcentinib in ACCORD Trial

Bergen, Norway - 02 June 2020 -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces

Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF- 100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

MIAMI, June 02, 2020 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) (Relief) and its U.S. partner, NeuroRx, Inc. today announced treatment of the first patients with RLF-100 at the Unive

Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients

CHESTERBROOK, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cen

AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment

VANCOUVER, British Columbia, June 1, 2020 -- AbCellera today announced that LY-CoV555, the lead antibody from the collaboration between AbCellera and Eli Lilly and Company (Lilly), has entered into hu

Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 1, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19

Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids

BASEL, Switzerland, June 01, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it has submitted a New